Nivolumab or Pembrolizumab Combos in Advanced Kidney Cancer?
Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.
Medscape Medical News
source https://www.medscape.com/viewarticle/986820?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/986820?src=rss
Comments
Post a Comment